These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 7995734)

  • 1. NSAIDs questionable as first-line therapy for rheumatic conditions in the elderly.
    Salach RH; Calabrese LH
    J Am Osteopath Assoc; 1994 Sep; 94(9):714, 766. PubMed ID: 7995734
    [No Abstract]   [Full Text] [Related]  

  • 2. The appropriate use of NSAIDs in arthritic conditions.
    Moskowitz RW
    Am J Orthop (Belle Mead NJ); 1996 Sep; 25(9 Suppl):4-6. PubMed ID: 8886211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [NSAID therapy. Gastrointestinal risks of classic NSAID are underestimated].
    MMW Fortschr Med; 2010 May; 152(20):46-7. PubMed ID: 20552882
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-inflammatory efficacy versus gastrointestinal safety: a dilemma resolved? Introduction.
    Bach GL
    Scand J Rheumatol Suppl; 1992; 96():5-6. PubMed ID: 1439625
    [No Abstract]   [Full Text] [Related]  

  • 5. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious gastrointestinal events from low dose analgesic use.
    Tarone RE; Lipworth L; McLaughlin JK
    J Rheumatol; 2004 May; 31(5):1008-9; author reply 1010-1. PubMed ID: 15124269
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical experience with cyclooxygenase-2 inhibitors.
    Lanas A
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non steroidal anti-inflammatory drugs. Risk factors versus benefits.
    Savvas P; Brooks PM
    Aust Fam Physician; 1991 Dec; 20(12):1726-9, 1732-3. PubMed ID: 1805774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study.
    Singh G; Ramey DR; Morfeld D; Shi H; Hatoum HT; Fries JF
    Arch Intern Med; 1996 Jul; 156(14):1530-6. PubMed ID: 8687261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated.
    Metcalfe S; Dougherty S; McNee W
    BMJ; 2003 Feb; 326(7384):334; author reply 334. PubMed ID: 12575714
    [No Abstract]   [Full Text] [Related]  

  • 13. Keeping patients with arthritis out of the hospital.
    Spiegel M
    Manag Care Interface; 1998 Jun; 11(6):81-5. PubMed ID: 10181565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2 inhibitors.
    Brooks PM; Day RO
    Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
    Steinfeld S; Bjørke PA
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adverse effects of non-steroidal antirheumatic drugs with special reference to the gastrointestinal tract].
    Hackenthal E
    Z Rheumatol; 1987; 46 Suppl 1():83-8. PubMed ID: 3439373
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ; Wentworth C; Burke TA; Makuch RW
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A decision analysis model in the evaluation of NSAIDs in a managed care setting: a case study.
    Brixner DI
    Med Interface; 1994 Nov; 7(11):145-50. PubMed ID: 10138701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Symptomatic therapy of arthrosis and rheumatoid arthritis. Who will benefit from Coxib?].
    MMW Fortschr Med; 2002 Apr; 144(14):53. PubMed ID: 12014284
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
    Simon LS; Hatoum HT; Bittman RM; Archambault WT; Polisson RP
    Fam Med; 1996 Mar; 28(3):204-10. PubMed ID: 8900554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.